Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results

Xenon Pharmaceuticals (NASDAQ:XENE) posted its earnings results on Thursday. The biopharmaceutical company reported ($1.11) EPS for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.05, FiscalAI reports. During the same period in the previous year, the company posted ($1.07) earnings per share.

Here are the key takeaways from Xenon Pharmaceuticals’ conference call:

• Atera demand significantly exceeded expectations, with booked orders already well above the approximately 40 instruments the company expects to ship in 2026. Management said demand—not customer interest—is the constraint, with manufacturing capacity limiting near-term shipments.
• 10x raised its 2026 revenue outlook to $610 million–$630 million, implying 2%–5% underlying growth excluding settlement revenue. Second-quarter revenue was $151 million, or $149.4 million excluding the $1.6 million Takara settlement, while gross margin improved to 74%.
• Total instrument revenue fell 47% year over year, as customers delayed Xenium and Visium purchases ahead of Atera’s launch. Management expects a modest sequential revenue decline in Q3 from continued spatial transition effects before a significant Q4 increase as Atera shipments ramp.
• Core consumables remained resilient, with total consumables revenue up 7%, spatial consumables up 16%, and single-cell reaction volumes growing at a double-digit rate driven by Flex Apex. Management also characterized AI-driven demand for high-quality single-cell and spatial data as a significant long-term structural tailwind.
• Academic funding conditions remain tenuous; grant sentiment is improving, but funding has not yet translated consistently into purchasing because of allocation delays, oversight, and order-processing bottlenecks. The company’s guidance assumes the current macro environment persists rather than any meaningful academic-market recovery.

Xenon Pharmaceuticals Trading Down 1.8%

Shares of XENE opened at $63.36 on Friday. The company’s 50 day simple moving average is $60.24 and its 200-day simple moving average is $54.20. The firm has a market cap of $6.13 billion, a PE ratio of -13.37 and a beta of 0.62. Xenon Pharmaceuticals has a 12-month low of $32.78 and a 12-month high of $72.66.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on XENE. JPMorgan Chase & Co. boosted their price target on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. Royal Bank Of Canada dropped their price objective on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating for the company in a report on Friday. Wells Fargo & Company reaffirmed an “overweight” rating and set a $69.00 target price on shares of Xenon Pharmaceuticals in a research note on Sunday, May 10th. Needham & Company LLC reduced their target price on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Finally, Wall Street Zen raised shares of Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $77.13.

Insiders Place Their Bets

In other news, Director Gillian Cannon sold 1,190 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the sale, the director owned 1,455 shares in the company, valued at approximately $77,318.70. This represents a 44.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gary Patou sold 1,322 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $70,251.08. Following the transaction, the director directly owned 24,896 shares in the company, valued at approximately $1,322,973.44. This represents a 5.04% decrease in their position. The SEC filing for this sale provides additional information. 2.91% of the stock is owned by corporate insiders.

Institutional Trading of Xenon Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Danske Bank A S acquired a new position in shares of Xenon Pharmaceuticals in the third quarter valued at approximately $32,000. Kestra Advisory Services LLC acquired a new stake in shares of Xenon Pharmaceuticals during the fourth quarter worth $33,000. Osaic Holdings Inc. grew its position in Xenon Pharmaceuticals by 541.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 1,034 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Xenon Pharmaceuticals in the 4th quarter valued at $43,000. Finally, State of Wyoming increased its stake in Xenon Pharmaceuticals by 30.4% in the 4th quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 350 shares during the period. 95.45% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Azetukalner NDA filing remains on track: Following an FDA meeting, RBC said Xenon still expects to submit a New Drug Application for azetukalner later this quarter. The filing is a major near-term catalyst for the company’s lead product candidate. Xenon Pharmaceuticals’ Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says
• Positive Sentiment: Quarterly loss beat expectations: Xenon reported a second-quarter adjusted loss of $1.11 per share, narrower than analysts’ expected $1.16 loss. Management also said its cash position should fund operations into 2029, reducing immediate financing and dilution concerns. XENE’s Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
• Neutral Sentiment: Pipeline remains the investment focus: Xenon has no reported product sales, so valuation depends largely on azetukalner’s clinical and regulatory progress. The company’s earnings call emphasized development plans and the anticipated NDA submission rather than near-term commercial revenue. Xenon Pharmaceuticals Q2 2026 Earnings Call Transcript
• Negative Sentiment: Losses continue to widen year over year: Although the quarterly loss beat estimates, the reported per-share loss was worse than the $1.07 loss recorded in the same period last year. With sales still nil and the company continuing to fund research and development, investors remain sensitive to execution and regulatory risks. Xenon Pharmaceuticals Q2 Loss Widens

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.